nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP1A1—Clonidine—glaucoma	0.0452	0.095	CbGbCtD
Gefitinib—CYP2D6—Carteolol—glaucoma	0.0449	0.0944	CbGbCtD
Gefitinib—CYP2D6—Betaxolol—glaucoma	0.0303	0.0638	CbGbCtD
Gefitinib—CYP2C19—Methazolamide—glaucoma	0.0303	0.0636	CbGbCtD
Gefitinib—SBK1—cornea—glaucoma	0.0294	0.59	CbGeAlD
Gefitinib—CYP2C9—Diclofenamide—glaucoma	0.0292	0.0614	CbGbCtD
Gefitinib—CYP2C9—Dorzolamide—glaucoma	0.0282	0.0593	CbGbCtD
Gefitinib—CYP3A5—Clonidine—glaucoma	0.0271	0.057	CbGbCtD
Gefitinib—CYP2C19—Timolol—glaucoma	0.0257	0.0541	CbGbCtD
Gefitinib—CYP2C9—Methazolamide—glaucoma	0.0251	0.0529	CbGbCtD
Gefitinib—CYP2D6—Methazolamide—glaucoma	0.023	0.0484	CbGbCtD
Gefitinib—CYP3A4—Pilocarpine—glaucoma	0.0216	0.0455	CbGbCtD
Gefitinib—ABCB1—Timolol—glaucoma	0.0208	0.0436	CbGbCtD
Gefitinib—CYP2D6—Timolol—glaucoma	0.0196	0.0411	CbGbCtD
Gefitinib—ABCB1—Clonidine—glaucoma	0.0176	0.0371	CbGbCtD
Gefitinib—CYP3A4—Brinzolamide—glaucoma	0.017	0.0357	CbGbCtD
Gefitinib—CYP2D6—Clonidine—glaucoma	0.0166	0.035	CbGbCtD
Gefitinib—CYP3A4—Dorzolamide—glaucoma	0.0164	0.0345	CbGbCtD
Gefitinib—CYP3A4—Methazolamide—glaucoma	0.0146	0.0307	CbGbCtD
Gefitinib—CYP3A4—Acetazolamide—glaucoma	0.0117	0.0246	CbGbCtD
Gefitinib—CYP3A4—Clonidine—glaucoma	0.0106	0.0222	CbGbCtD
Gefitinib—Bosutinib—TBK1—glaucoma	0.00432	0.646	CrCbGaD
Gefitinib—SBK1—eye—glaucoma	0.00363	0.0727	CbGeAlD
Gefitinib—SBK1—retina—glaucoma	0.0036	0.0721	CbGeAlD
Gefitinib—CSNK1E—retina—glaucoma	0.00199	0.0398	CbGeAlD
Gefitinib—ERBB3—connective tissue—glaucoma	0.00186	0.0374	CbGeAlD
Gefitinib—MKNK2—eye—glaucoma	0.00184	0.0369	CbGeAlD
Gefitinib—MKNK2—retina—glaucoma	0.00182	0.0365	CbGeAlD
Gefitinib—MKNK1—eye—glaucoma	0.00182	0.0364	CbGeAlD
Gefitinib—MKNK1—retina—glaucoma	0.0018	0.0361	CbGeAlD
Gefitinib—MKNK2—connective tissue—glaucoma	0.00177	0.0355	CbGeAlD
Gefitinib—Erlotinib—CYP1B1—glaucoma	0.00136	0.204	CrCbGaD
Gefitinib—MKNK1—Pindolol—Carteolol—glaucoma	0.00115	0.177	CbGdCrCtD
Gefitinib—MKNK1—Pindolol—Levobunolol—glaucoma	0.00115	0.177	CbGdCrCtD
Gefitinib—MKNK1—Pindolol—Metipranolol—glaucoma	0.0011	0.169	CbGdCrCtD
Gefitinib—Vandetanib—VEGFA—glaucoma	0.001	0.15	CrCbGaD
Gefitinib—ERBB3—Alprenolol—Metipranolol—glaucoma	0.000995	0.153	CbGdCrCtD
Gefitinib—MKNK1—Pindolol—Betaxolol—glaucoma	0.000767	0.118	CbGdCrCtD
Gefitinib—ERBB3—Alprenolol—Betaxolol—glaucoma	0.000696	0.107	CbGdCrCtD
Gefitinib—CHEK2—Treprostinil—Latanoprost—glaucoma	0.000643	0.099	CbGdCrCtD
Gefitinib—Weight decreased—Betaxolol—glaucoma	0.000328	0.00111	CcSEcCtD
Gefitinib—Pain—Apraclonidine—glaucoma	0.000327	0.00111	CcSEcCtD
Gefitinib—Constipation—Apraclonidine—glaucoma	0.000327	0.00111	CcSEcCtD
Gefitinib—Infection—Brimonidine—glaucoma	0.000326	0.0011	CcSEcCtD
Gefitinib—Pneumonia—Betaxolol—glaucoma	0.000325	0.0011	CcSEcCtD
Gefitinib—Nausea—Carteolol—glaucoma	0.000324	0.0011	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000323	0.0011	CcSEcCtD
Gefitinib—Shock—Brimonidine—glaucoma	0.000323	0.00109	CcSEcCtD
Gefitinib—Infestation—Betaxolol—glaucoma	0.000323	0.00109	CcSEcCtD
Gefitinib—Infestation NOS—Betaxolol—glaucoma	0.000323	0.00109	CcSEcCtD
Gefitinib—Nervous system disorder—Brimonidine—glaucoma	0.000322	0.00109	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Bimatoprost—glaucoma	0.00032	0.00108	CcSEcCtD
Gefitinib—Dry mouth—Dorzolamide—glaucoma	0.00032	0.00108	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.000319	0.00108	CcSEcCtD
Gefitinib—Skin disorder—Brimonidine—glaucoma	0.000319	0.00108	CcSEcCtD
Gefitinib—Nausea—Diclofenamide—glaucoma	0.000319	0.00108	CcSEcCtD
Gefitinib—Dry mouth—Travoprost—glaucoma	0.000318	0.00108	CcSEcCtD
Gefitinib—ABCB1—retina—glaucoma	0.000317	0.00636	CbGeAlD
Gefitinib—Pain—Bimatoprost—glaucoma	0.000317	0.00107	CcSEcCtD
Gefitinib—Cough—Pilocarpine—glaucoma	0.000317	0.00107	CcSEcCtD
Gefitinib—Stomatitis—Betaxolol—glaucoma	0.000315	0.00107	CcSEcCtD
Gefitinib—Dry mouth—Brinzolamide—glaucoma	0.000314	0.00107	CcSEcCtD
Gefitinib—Vomiting—Methazolamide—glaucoma	0.000314	0.00106	CcSEcCtD
Gefitinib—Conjunctivitis—Betaxolol—glaucoma	0.000314	0.00106	CcSEcCtD
Gefitinib—Gastrointestinal pain—Apraclonidine—glaucoma	0.000313	0.00106	CcSEcCtD
Gefitinib—Rash—Methazolamide—glaucoma	0.000311	0.00106	CcSEcCtD
Gefitinib—Dermatitis—Methazolamide—glaucoma	0.000311	0.00105	CcSEcCtD
Gefitinib—Eye disorder—Clonidine—glaucoma	0.000311	0.00105	CcSEcCtD
Gefitinib—Nausea—Carbachol—glaucoma	0.000311	0.00105	CcSEcCtD
Gefitinib—Infection—Travoprost—glaucoma	0.00031	0.00105	CcSEcCtD
Gefitinib—Cardiac disorder—Clonidine—glaucoma	0.000309	0.00105	CcSEcCtD
Gefitinib—Shock—Dorzolamide—glaucoma	0.000308	0.00104	CcSEcCtD
Gefitinib—Hypotension—Brimonidine—glaucoma	0.000307	0.00104	CcSEcCtD
Gefitinib—Nausea—Levobunolol—glaucoma	0.000306	0.00104	CcSEcCtD
Gefitinib—Infection—Brinzolamide—glaucoma	0.000306	0.00104	CcSEcCtD
Gefitinib—Nervous system disorder—Travoprost—glaucoma	0.000306	0.00104	CcSEcCtD
Gefitinib—Epistaxis—Betaxolol—glaucoma	0.000304	0.00103	CcSEcCtD
Gefitinib—Skin disorder—Travoprost—glaucoma	0.000303	0.00103	CcSEcCtD
Gefitinib—Abdominal pain—Apraclonidine—glaucoma	0.000302	0.00102	CcSEcCtD
Gefitinib—Nervous system disorder—Brinzolamide—glaucoma	0.000302	0.00102	CcSEcCtD
Gefitinib—Angiopathy—Clonidine—glaucoma	0.000302	0.00102	CcSEcCtD
Gefitinib—Rash—Latanoprost—glaucoma	0.000301	0.00102	CcSEcCtD
Gefitinib—Dermatitis—Latanoprost—glaucoma	0.000301	0.00102	CcSEcCtD
Gefitinib—Mediastinal disorder—Clonidine—glaucoma	0.0003	0.00102	CcSEcCtD
Gefitinib—Skin disorder—Brinzolamide—glaucoma	0.000299	0.00101	CcSEcCtD
Gefitinib—Anorexia—Dorzolamide—glaucoma	0.000299	0.00101	CcSEcCtD
Gefitinib—Arrhythmia—Clonidine—glaucoma	0.000297	0.00101	CcSEcCtD
Gefitinib—Decreased appetite—Acetazolamide—glaucoma	0.000297	0.00101	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000295	0.001	CcSEcCtD
Gefitinib—Fatigue—Acetazolamide—glaucoma	0.000295	0.000999	CcSEcCtD
Gefitinib—Infection—Pilocarpine—glaucoma	0.000294	0.000997	CcSEcCtD
Gefitinib—Alopecia—Clonidine—glaucoma	0.000294	0.000997	CcSEcCtD
Gefitinib—Nausea—Methazolamide—glaucoma	0.000293	0.000994	CcSEcCtD
Gefitinib—Hypotension—Dorzolamide—glaucoma	0.000293	0.000992	CcSEcCtD
Gefitinib—Dyspnoea—Brimonidine—glaucoma	0.000293	0.000991	CcSEcCtD
Gefitinib—Hypotension—Travoprost—glaucoma	0.000292	0.000988	CcSEcCtD
Gefitinib—Shock—Pilocarpine—glaucoma	0.000291	0.000987	CcSEcCtD
Gefitinib—Thrombocytopenia—Pilocarpine—glaucoma	0.00029	0.000983	CcSEcCtD
Gefitinib—Hypotension—Brinzolamide—glaucoma	0.000288	0.000976	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000283	0.00096	CcSEcCtD
Gefitinib—Fatigue—Brimonidine—glaucoma	0.000283	0.000959	CcSEcCtD
Gefitinib—Anorexia—Pilocarpine—glaucoma	0.000282	0.000957	CcSEcCtD
Gefitinib—Hypersensitivity—Apraclonidine—glaucoma	0.000282	0.000954	CcSEcCtD
Gefitinib—Pain—Brimonidine—glaucoma	0.000281	0.000951	CcSEcCtD
Gefitinib—Dyspnoea—Dorzolamide—glaucoma	0.000279	0.000947	CcSEcCtD
Gefitinib—Dyspnoea—Travoprost—glaucoma	0.000278	0.000943	CcSEcCtD
Gefitinib—Hypotension—Pilocarpine—glaucoma	0.000277	0.000938	CcSEcCtD
Gefitinib—Dyspnoea—Brinzolamide—glaucoma	0.000275	0.000931	CcSEcCtD
Gefitinib—Asthenia—Apraclonidine—glaucoma	0.000274	0.000929	CcSEcCtD
Gefitinib—Decreased appetite—Dorzolamide—glaucoma	0.000272	0.000923	CcSEcCtD
Gefitinib—Urticaria—Acetazolamide—glaucoma	0.000272	0.00092	CcSEcCtD
Gefitinib—Eye disorder—Betaxolol—glaucoma	0.000271	0.000918	CcSEcCtD
Gefitinib—Pruritus—Apraclonidine—glaucoma	0.00027	0.000916	CcSEcCtD
Gefitinib—Body temperature increased—Acetazolamide—glaucoma	0.00027	0.000916	CcSEcCtD
Gefitinib—Fatigue—Dorzolamide—glaucoma	0.00027	0.000916	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Travoprost—glaucoma	0.000269	0.000913	CcSEcCtD
Gefitinib—Fatigue—Travoprost—glaucoma	0.000269	0.000912	CcSEcCtD
Gefitinib—Cardiac disorder—Betaxolol—glaucoma	0.000269	0.000911	CcSEcCtD
Gefitinib—Pain—Dorzolamide—glaucoma	0.000268	0.000908	CcSEcCtD
Gefitinib—Decreased appetite—Brinzolamide—glaucoma	0.000268	0.000908	CcSEcCtD
Gefitinib—Weight decreased—Timolol—glaucoma	0.000268	0.000907	CcSEcCtD
Gefitinib—Constipation—Travoprost—glaucoma	0.000267	0.000904	CcSEcCtD
Gefitinib—Pain—Travoprost—glaucoma	0.000267	0.000904	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000266	0.000901	CcSEcCtD
Gefitinib—Asthenia—Bimatoprost—glaucoma	0.000266	0.000901	CcSEcCtD
Gefitinib—Fatigue—Brinzolamide—glaucoma	0.000266	0.0009	CcSEcCtD
Gefitinib—Angioedema—Clonidine—glaucoma	0.000265	0.000897	CcSEcCtD
Gefitinib—Dyspnoea—Pilocarpine—glaucoma	0.000264	0.000895	CcSEcCtD
Gefitinib—Pain—Brinzolamide—glaucoma	0.000263	0.000893	CcSEcCtD
Gefitinib—Angiopathy—Betaxolol—glaucoma	0.000263	0.000891	CcSEcCtD
Gefitinib—Pruritus—Bimatoprost—glaucoma	0.000262	0.000888	CcSEcCtD
Gefitinib—Diarrhoea—Apraclonidine—glaucoma	0.000262	0.000886	CcSEcCtD
Gefitinib—Malaise—Clonidine—glaucoma	0.000261	0.000885	CcSEcCtD
Gefitinib—Mediastinal disorder—Betaxolol—glaucoma	0.000261	0.000885	CcSEcCtD
Gefitinib—Arrhythmia—Betaxolol—glaucoma	0.000259	0.000877	CcSEcCtD
Gefitinib—Decreased appetite—Pilocarpine—glaucoma	0.000257	0.000872	CcSEcCtD
Gefitinib—Conjunctivitis—Timolol—glaucoma	0.000256	0.000869	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dorzolamide—glaucoma	0.000256	0.000868	CcSEcCtD
Gefitinib—Alopecia—Betaxolol—glaucoma	0.000256	0.000868	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000256	0.000866	CcSEcCtD
Gefitinib—Gastrointestinal pain—Travoprost—glaucoma	0.000255	0.000865	CcSEcCtD
Gefitinib—Pain—Pilocarpine—glaucoma	0.000253	0.000858	CcSEcCtD
Gefitinib—Constipation—Pilocarpine—glaucoma	0.000253	0.000858	CcSEcCtD
Gefitinib—Cough—Clonidine—glaucoma	0.000253	0.000857	CcSEcCtD
Gefitinib—Malnutrition—Betaxolol—glaucoma	0.000252	0.000855	CcSEcCtD
Gefitinib—Urticaria—Dorzolamide—glaucoma	0.000249	0.000844	CcSEcCtD
Gefitinib—Epistaxis—Timolol—glaucoma	0.000249	0.000843	CcSEcCtD
Gefitinib—Abdominal pain—Dorzolamide—glaucoma	0.000248	0.00084	CcSEcCtD
Gefitinib—Body temperature increased—Dorzolamide—glaucoma	0.000248	0.00084	CcSEcCtD
Gefitinib—Abdominal pain—Travoprost—glaucoma	0.000247	0.000836	CcSEcCtD
Gefitinib—Asthenia—Acetazolamide—glaucoma	0.000245	0.000831	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000245	0.00083	CcSEcCtD
Gefitinib—Urticaria—Brinzolamide—glaucoma	0.000245	0.000829	CcSEcCtD
Gefitinib—Vomiting—Apraclonidine—glaucoma	0.000243	0.000824	CcSEcCtD
Gefitinib—Gastrointestinal pain—Pilocarpine—glaucoma	0.000242	0.000821	CcSEcCtD
Gefitinib—Hypersensitivity—Brimonidine—glaucoma	0.000242	0.000819	CcSEcCtD
Gefitinib—Dry mouth—Clonidine—glaucoma	0.000241	0.000818	CcSEcCtD
Gefitinib—Dermatitis—Apraclonidine—glaucoma	0.000241	0.000816	CcSEcCtD
Gefitinib—Asthenia—Brimonidine—glaucoma	0.000235	0.000798	CcSEcCtD
Gefitinib—Infection—Clonidine—glaucoma	0.000235	0.000796	CcSEcCtD
Gefitinib—Abdominal pain—Pilocarpine—glaucoma	0.000234	0.000793	CcSEcCtD
Gefitinib—Body temperature increased—Pilocarpine—glaucoma	0.000234	0.000793	CcSEcCtD
Gefitinib—Diarrhoea—Acetazolamide—glaucoma	0.000234	0.000793	CcSEcCtD
Gefitinib—Rash—Bimatoprost—glaucoma	0.000234	0.000792	CcSEcCtD
Gefitinib—Dermatitis—Bimatoprost—glaucoma	0.000233	0.000791	CcSEcCtD
Gefitinib—Oedema peripheral—Timolol—glaucoma	0.000233	0.00079	CcSEcCtD
Gefitinib—Anaemia—Betaxolol—glaucoma	0.000233	0.00079	CcSEcCtD
Gefitinib—Shock—Clonidine—glaucoma	0.000233	0.000788	CcSEcCtD
Gefitinib—Pruritus—Brimonidine—glaucoma	0.000232	0.000787	CcSEcCtD
Gefitinib—Nervous system disorder—Clonidine—glaucoma	0.000232	0.000786	CcSEcCtD
Gefitinib—Thrombocytopenia—Clonidine—glaucoma	0.000232	0.000785	CcSEcCtD
Gefitinib—Hypersensitivity—Dorzolamide—glaucoma	0.000231	0.000782	CcSEcCtD
Gefitinib—Hypersensitivity—Travoprost—glaucoma	0.00023	0.000779	CcSEcCtD
Gefitinib—Skin disorder—Clonidine—glaucoma	0.00023	0.000778	CcSEcCtD
Gefitinib—Malaise—Betaxolol—glaucoma	0.000228	0.000771	CcSEcCtD
Gefitinib—Nausea—Apraclonidine—glaucoma	0.000227	0.000769	CcSEcCtD
Gefitinib—Hypersensitivity—Brinzolamide—glaucoma	0.000227	0.000769	CcSEcCtD
Gefitinib—Anorexia—Clonidine—glaucoma	0.000225	0.000764	CcSEcCtD
Gefitinib—Asthenia—Dorzolamide—glaucoma	0.000225	0.000762	CcSEcCtD
Gefitinib—Asthenia—Travoprost—glaucoma	0.000224	0.000759	CcSEcCtD
Gefitinib—Pruritus—Dorzolamide—glaucoma	0.000222	0.000751	CcSEcCtD
Gefitinib—Eye disorder—Timolol—glaucoma	0.000221	0.00075	CcSEcCtD
Gefitinib—Asthenia—Brinzolamide—glaucoma	0.000221	0.000749	CcSEcCtD
Gefitinib—Hypotension—Clonidine—glaucoma	0.000221	0.000749	CcSEcCtD
Gefitinib—Pruritus—Travoprost—glaucoma	0.000221	0.000748	CcSEcCtD
Gefitinib—Cough—Betaxolol—glaucoma	0.00022	0.000746	CcSEcCtD
Gefitinib—Nausea—Bimatoprost—glaucoma	0.00022	0.000746	CcSEcCtD
Gefitinib—Cardiac disorder—Timolol—glaucoma	0.00022	0.000745	CcSEcCtD
Gefitinib—Hypersensitivity—Pilocarpine—glaucoma	0.000218	0.000739	CcSEcCtD
Gefitinib—Pruritus—Brinzolamide—glaucoma	0.000218	0.000739	CcSEcCtD
Gefitinib—Vomiting—Acetazolamide—glaucoma	0.000217	0.000737	CcSEcCtD
Gefitinib—Angiopathy—Timolol—glaucoma	0.000215	0.000728	CcSEcCtD
Gefitinib—Diarrhoea—Dorzolamide—glaucoma	0.000214	0.000727	CcSEcCtD
Gefitinib—Diarrhoea—Travoprost—glaucoma	0.000214	0.000723	CcSEcCtD
Gefitinib—Mediastinal disorder—Timolol—glaucoma	0.000213	0.000723	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000213	0.000723	CcSEcCtD
Gefitinib—Asthenia—Pilocarpine—glaucoma	0.000212	0.00072	CcSEcCtD
Gefitinib—Arrhythmia—Timolol—glaucoma	0.000211	0.000717	CcSEcCtD
Gefitinib—Dyspnoea—Clonidine—glaucoma	0.000211	0.000714	CcSEcCtD
Gefitinib—Diarrhoea—Brinzolamide—glaucoma	0.000211	0.000714	CcSEcCtD
Gefitinib—Dry mouth—Betaxolol—glaucoma	0.00021	0.000712	CcSEcCtD
Gefitinib—Pruritus—Pilocarpine—glaucoma	0.00021	0.00071	CcSEcCtD
Gefitinib—Alopecia—Timolol—glaucoma	0.000209	0.000709	CcSEcCtD
Gefitinib—Rash—Brimonidine—glaucoma	0.000207	0.000701	CcSEcCtD
Gefitinib—Dermatitis—Brimonidine—glaucoma	0.000207	0.0007	CcSEcCtD
Gefitinib—Malnutrition—Timolol—glaucoma	0.000206	0.000698	CcSEcCtD
Gefitinib—Decreased appetite—Clonidine—glaucoma	0.000206	0.000697	CcSEcCtD
Gefitinib—Infection—Betaxolol—glaucoma	0.000205	0.000693	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Clonidine—glaucoma	0.000204	0.000692	CcSEcCtD
Gefitinib—Fatigue—Clonidine—glaucoma	0.000204	0.000691	CcSEcCtD
Gefitinib—Nausea—Acetazolamide—glaucoma	0.000203	0.000688	CcSEcCtD
Gefitinib—Diarrhoea—Pilocarpine—glaucoma	0.000203	0.000687	CcSEcCtD
Gefitinib—Shock—Betaxolol—glaucoma	0.000203	0.000686	CcSEcCtD
Gefitinib—Pain—Clonidine—glaucoma	0.000202	0.000685	CcSEcCtD
Gefitinib—Constipation—Clonidine—glaucoma	0.000202	0.000685	CcSEcCtD
Gefitinib—Nervous system disorder—Betaxolol—glaucoma	0.000202	0.000684	CcSEcCtD
Gefitinib—Thrombocytopenia—Betaxolol—glaucoma	0.000202	0.000683	CcSEcCtD
Gefitinib—Skin disorder—Betaxolol—glaucoma	0.0002	0.000678	CcSEcCtD
Gefitinib—Vomiting—Dorzolamide—glaucoma	0.000199	0.000675	CcSEcCtD
Gefitinib—Rash—Dorzolamide—glaucoma	0.000198	0.00067	CcSEcCtD
Gefitinib—Dermatitis—Dorzolamide—glaucoma	0.000197	0.000669	CcSEcCtD
Gefitinib—Rash—Travoprost—glaucoma	0.000197	0.000667	CcSEcCtD
Gefitinib—Dermatitis—Travoprost—glaucoma	0.000197	0.000666	CcSEcCtD
Gefitinib—Anorexia—Betaxolol—glaucoma	0.000196	0.000665	CcSEcCtD
Gefitinib—Vomiting—Brinzolamide—glaucoma	0.000196	0.000664	CcSEcCtD
Gefitinib—Nausea—Brimonidine—glaucoma	0.000195	0.000661	CcSEcCtD
Gefitinib—Rash—Brinzolamide—glaucoma	0.000194	0.000658	CcSEcCtD
Gefitinib—Dermatitis—Brinzolamide—glaucoma	0.000194	0.000658	CcSEcCtD
Gefitinib—Gastrointestinal pain—Clonidine—glaucoma	0.000193	0.000655	CcSEcCtD
Gefitinib—Hypotension—Betaxolol—glaucoma	0.000192	0.000652	CcSEcCtD
Gefitinib—Angioedema—Timolol—glaucoma	0.000188	0.000638	CcSEcCtD
Gefitinib—Vomiting—Pilocarpine—glaucoma	0.000188	0.000638	CcSEcCtD
Gefitinib—Urticaria—Clonidine—glaucoma	0.000188	0.000637	CcSEcCtD
Gefitinib—Abdominal pain—Clonidine—glaucoma	0.000187	0.000633	CcSEcCtD
Gefitinib—Body temperature increased—Clonidine—glaucoma	0.000187	0.000633	CcSEcCtD
Gefitinib—Rash—Pilocarpine—glaucoma	0.000187	0.000633	CcSEcCtD
Gefitinib—Dermatitis—Pilocarpine—glaucoma	0.000187	0.000632	CcSEcCtD
Gefitinib—Nausea—Dorzolamide—glaucoma	0.000186	0.000631	CcSEcCtD
Gefitinib—Nausea—Travoprost—glaucoma	0.000185	0.000628	CcSEcCtD
Gefitinib—Dyspnoea—Betaxolol—glaucoma	0.000184	0.000622	CcSEcCtD
Gefitinib—Nausea—Brinzolamide—glaucoma	0.000183	0.00062	CcSEcCtD
Gefitinib—Cough—Timolol—glaucoma	0.00018	0.000609	CcSEcCtD
Gefitinib—Decreased appetite—Betaxolol—glaucoma	0.000179	0.000606	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000178	0.000602	CcSEcCtD
Gefitinib—Fatigue—Betaxolol—glaucoma	0.000178	0.000601	CcSEcCtD
Gefitinib—Pain—Betaxolol—glaucoma	0.000176	0.000597	CcSEcCtD
Gefitinib—Constipation—Betaxolol—glaucoma	0.000176	0.000597	CcSEcCtD
Gefitinib—Nausea—Pilocarpine—glaucoma	0.000176	0.000596	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000174	0.00059	CcSEcCtD
Gefitinib—Hypersensitivity—Clonidine—glaucoma	0.000174	0.00059	CcSEcCtD
Gefitinib—Dry mouth—Timolol—glaucoma	0.000172	0.000581	CcSEcCtD
Gefitinib—Asthenia—Clonidine—glaucoma	0.00017	0.000575	CcSEcCtD
Gefitinib—Pruritus—Clonidine—glaucoma	0.000167	0.000567	CcSEcCtD
Gefitinib—Infection—Timolol—glaucoma	0.000167	0.000566	CcSEcCtD
Gefitinib—Shock—Timolol—glaucoma	0.000165	0.000561	CcSEcCtD
Gefitinib—Nervous system disorder—Timolol—glaucoma	0.000165	0.000559	CcSEcCtD
Gefitinib—Urticaria—Betaxolol—glaucoma	0.000164	0.000554	CcSEcCtD
Gefitinib—Skin disorder—Timolol—glaucoma	0.000163	0.000554	CcSEcCtD
Gefitinib—Body temperature increased—Betaxolol—glaucoma	0.000163	0.000552	CcSEcCtD
Gefitinib—Diarrhoea—Clonidine—glaucoma	0.000162	0.000548	CcSEcCtD
Gefitinib—Anorexia—Timolol—glaucoma	0.00016	0.000543	CcSEcCtD
Gefitinib—Hypotension—Timolol—glaucoma	0.000157	0.000533	CcSEcCtD
Gefitinib—Hypersensitivity—Betaxolol—glaucoma	0.000152	0.000514	CcSEcCtD
Gefitinib—Vomiting—Clonidine—glaucoma	0.00015	0.00051	CcSEcCtD
Gefitinib—Dyspnoea—Timolol—glaucoma	0.00015	0.000508	CcSEcCtD
Gefitinib—Rash—Clonidine—glaucoma	0.000149	0.000505	CcSEcCtD
Gefitinib—Dermatitis—Clonidine—glaucoma	0.000149	0.000505	CcSEcCtD
Gefitinib—Asthenia—Betaxolol—glaucoma	0.000148	0.000501	CcSEcCtD
Gefitinib—Decreased appetite—Timolol—glaucoma	0.000146	0.000495	CcSEcCtD
Gefitinib—Pruritus—Betaxolol—glaucoma	0.000146	0.000494	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Timolol—glaucoma	0.000145	0.000492	CcSEcCtD
Gefitinib—Fatigue—Timolol—glaucoma	0.000145	0.000491	CcSEcCtD
Gefitinib—Pain—Timolol—glaucoma	0.000144	0.000487	CcSEcCtD
Gefitinib—Diarrhoea—Betaxolol—glaucoma	0.000141	0.000477	CcSEcCtD
Gefitinib—Nausea—Clonidine—glaucoma	0.00014	0.000476	CcSEcCtD
Gefitinib—Gastrointestinal pain—Timolol—glaucoma	0.000138	0.000466	CcSEcCtD
Gefitinib—Urticaria—Timolol—glaucoma	0.000134	0.000453	CcSEcCtD
Gefitinib—Abdominal pain—Timolol—glaucoma	0.000133	0.000451	CcSEcCtD
Gefitinib—Body temperature increased—Timolol—glaucoma	0.000133	0.000451	CcSEcCtD
Gefitinib—Vomiting—Betaxolol—glaucoma	0.000131	0.000444	CcSEcCtD
Gefitinib—Rash—Betaxolol—glaucoma	0.00013	0.00044	CcSEcCtD
Gefitinib—Dermatitis—Betaxolol—glaucoma	0.00013	0.000439	CcSEcCtD
Gefitinib—Hypersensitivity—Timolol—glaucoma	0.000124	0.00042	CcSEcCtD
Gefitinib—Nausea—Betaxolol—glaucoma	0.000122	0.000414	CcSEcCtD
Gefitinib—Asthenia—Timolol—glaucoma	0.000121	0.000409	CcSEcCtD
Gefitinib—Pruritus—Timolol—glaucoma	0.000119	0.000403	CcSEcCtD
Gefitinib—Diarrhoea—Timolol—glaucoma	0.000115	0.00039	CcSEcCtD
Gefitinib—Vomiting—Timolol—glaucoma	0.000107	0.000362	CcSEcCtD
Gefitinib—Rash—Timolol—glaucoma	0.000106	0.000359	CcSEcCtD
Gefitinib—Dermatitis—Timolol—glaucoma	0.000106	0.000359	CcSEcCtD
Gefitinib—Nausea—Timolol—glaucoma	9.99e-05	0.000339	CcSEcCtD
Gefitinib—ERBB3—Disease—CAV1—glaucoma	2.35e-05	0.000142	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP9—glaucoma	2.34e-05	0.000141	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—C3—glaucoma	2.34e-05	0.000141	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NOS3—glaucoma	2.33e-05	0.00014	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NTRK1—glaucoma	2.31e-05	0.000139	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—C3—glaucoma	2.3e-05	0.000138	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—BAD—glaucoma	2.29e-05	0.000138	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CA2—glaucoma	2.23e-05	0.000134	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP2—glaucoma	2.23e-05	0.000134	CbGpPWpGaD
Gefitinib—ERBB3—Disease—BAD—glaucoma	2.21e-05	0.000133	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CDKN2B—glaucoma	2.21e-05	0.000133	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HDAC9—glaucoma	2.21e-05	0.000133	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—BCL2L1—glaucoma	2.2e-05	0.000132	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—BAD—glaucoma	2.2e-05	0.000132	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CA1—glaucoma	2.19e-05	0.000132	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—APOE—glaucoma	2.18e-05	0.000131	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	2.18e-05	0.000131	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	2.18e-05	0.000131	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CAV1—glaucoma	2.16e-05	0.00013	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTGS2—glaucoma	2.13e-05	0.000128	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CA1—glaucoma	2.13e-05	0.000128	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SOD1—glaucoma	2.13e-05	0.000128	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CDKN2B—glaucoma	2.13e-05	0.000128	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EDN1—glaucoma	2.12e-05	0.000128	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CTSA—glaucoma	2.12e-05	0.000127	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—VEGFA—glaucoma	2.1e-05	0.000127	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NOS3—glaucoma	2.1e-05	0.000126	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CDKN1B—glaucoma	2.09e-05	0.000126	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CTSA—glaucoma	2.07e-05	0.000124	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	2.06e-05	0.000124	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—FN1—glaucoma	2.06e-05	0.000124	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EDN1—glaucoma	2.04e-05	0.000123	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—BAD—glaucoma	2.03e-05	0.000122	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NGFR—glaucoma	2.03e-05	0.000122	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CDKN1B—glaucoma	2.02e-05	0.000122	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CA1—glaucoma	2.01e-05	0.000121	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CA2—glaucoma	2e-05	0.00012	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—BAD—glaucoma	1.99e-05	0.00012	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CA1—glaucoma	1.99e-05	0.00012	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTT1—glaucoma	1.97e-05	0.000119	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.95e-05	0.000118	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.95e-05	0.000118	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CA2—glaucoma	1.95e-05	0.000117	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	1.95e-05	0.000117	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NGF—glaucoma	1.95e-05	0.000117	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CTSA—glaucoma	1.95e-05	0.000117	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CTSA—glaucoma	1.93e-05	0.000116	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—EDN1—glaucoma	1.93e-05	0.000116	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NTRK1—glaucoma	1.92e-05	0.000116	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NGF—glaucoma	1.88e-05	0.000113	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—C3—glaucoma	1.85e-05	0.000111	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CA2—glaucoma	1.84e-05	0.000111	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CA2—glaucoma	1.82e-05	0.00011	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TXN—glaucoma	1.82e-05	0.00011	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CDKN1B—glaucoma	1.82e-05	0.00011	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—C3—glaucoma	1.79e-05	0.000107	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.78e-05	0.000107	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.78e-05	0.000107	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS3—glaucoma	1.78e-05	0.000107	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN2B—glaucoma	1.77e-05	0.000107	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1A—glaucoma	1.75e-05	0.000105	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMO—glaucoma	1.73e-05	0.000104	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—APOE—glaucoma	1.72e-05	0.000104	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TXN—glaucoma	1.72e-05	0.000104	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CAV1—glaucoma	1.71e-05	0.000103	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EDN1—glaucoma	1.7e-05	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN2B—glaucoma	1.69e-05	0.000102	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—glaucoma	1.69e-05	0.000101	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—C3—glaucoma	1.68e-05	0.000101	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—glaucoma	1.67e-05	0.000101	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CDKN1B—glaucoma	1.67e-05	0.0001	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—APOE—glaucoma	1.66e-05	0.0001	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CAV1—glaucoma	1.65e-05	9.91e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	1.65e-05	9.91e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOS3—glaucoma	1.63e-05	9.84e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—glaucoma	1.63e-05	9.79e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FN1—glaucoma	1.63e-05	9.79e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MMP1—glaucoma	1.63e-05	9.78e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.62e-05	9.76e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—BAD—glaucoma	1.61e-05	9.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CDKN1B—glaucoma	1.59e-05	9.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NTRK2—glaucoma	1.58e-05	9.5e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP1B1—glaucoma	1.57e-05	9.45e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ABCA1—glaucoma	1.57e-05	9.45e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.57e-05	9.45e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TXN—glaucoma	1.57e-05	9.44e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FN1—glaucoma	1.57e-05	9.43e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NGF—glaucoma	1.56e-05	9.41e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—CAV1—glaucoma	1.56e-05	9.38e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.56e-05	9.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—BAD—glaucoma	1.55e-05	9.32e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CDKN1B—glaucoma	1.54e-05	9.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—C3—glaucoma	1.54e-05	9.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CDKN1B—glaucoma	1.53e-05	9.22e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VEGFA—glaucoma	1.51e-05	9.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—VEGFA—glaucoma	1.5e-05	9.04e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—C3—glaucoma	1.49e-05	8.95e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—FN1—glaucoma	1.48e-05	8.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BCL2L1—glaucoma	1.47e-05	8.86e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.43e-05	8.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTHFR—glaucoma	1.42e-05	8.54e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.42e-05	8.54e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CDKN1B—glaucoma	1.42e-05	8.52e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTT1—glaucoma	1.41e-05	8.5e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TXN—glaucoma	1.41e-05	8.48e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.39e-05	8.36e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CDKN1B—glaucoma	1.39e-05	8.36e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—APOE—glaucoma	1.38e-05	8.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TXN—glaucoma	1.37e-05	8.27e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CAV1—glaucoma	1.37e-05	8.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NGFR—glaucoma	1.35e-05	8.15e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTT1—glaucoma	1.33e-05	8.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BAD—glaucoma	1.33e-05	8.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—APOE—glaucoma	1.32e-05	7.95e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CA1—glaucoma	1.31e-05	7.91e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—glaucoma	1.31e-05	7.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CAV1—glaucoma	1.31e-05	7.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FN1—glaucoma	1.31e-05	7.85e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TXN—glaucoma	1.3e-05	7.8e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOS3—glaucoma	1.29e-05	7.77e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—BAD—glaucoma	1.29e-05	7.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—glaucoma	1.29e-05	7.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NTRK1—glaucoma	1.29e-05	7.74e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.29e-05	7.73e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TXN—glaucoma	1.28e-05	7.73e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.27e-05	7.66e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CTSA—glaucoma	1.27e-05	7.66e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTM1—glaucoma	1.26e-05	7.56e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOS3—glaucoma	1.25e-05	7.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—BAD—glaucoma	1.23e-05	7.41e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.23e-05	7.37e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTT1—glaucoma	1.22e-05	7.32e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CA2—glaucoma	1.2e-05	7.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN2B—glaucoma	1.19e-05	7.14e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS3—glaucoma	1.18e-05	7.09e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—glaucoma	1.18e-05	7.09e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.17e-05	7.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.16e-05	6.99e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—glaucoma	1.14e-05	6.88e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EDN1—glaucoma	1.14e-05	6.85e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP1B1—glaucoma	1.13e-05	6.77e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ABCA1—glaucoma	1.13e-05	6.77e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CDKN1B—glaucoma	1.12e-05	6.73e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MTHFR—glaucoma	1.11e-05	6.68e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTT1—glaucoma	1.09e-05	6.57e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CDKN1B—glaucoma	1.08e-05	6.49e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.08e-05	6.48e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTT1—glaucoma	1.07e-05	6.41e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ABCA1—glaucoma	1.06e-05	6.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP1B1—glaucoma	1.06e-05	6.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NGF—glaucoma	1.05e-05	6.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOS3—glaucoma	1.04e-05	6.24e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—glaucoma	1.04e-05	6.24e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—APOE—glaucoma	1.03e-05	6.22e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CAV1—glaucoma	1.02e-05	6.16e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTT1—glaucoma	1e-05	6.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—glaucoma	9.99e-06	6.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTT1—glaucoma	9.96e-06	5.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—C3—glaucoma	9.94e-06	5.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS3—glaucoma	9.9e-06	5.96e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	9.81e-06	5.9e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCA1—glaucoma	9.69e-06	5.83e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1B1—glaucoma	9.69e-06	5.83e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—glaucoma	9.31e-06	5.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1B—glaucoma	9.29e-06	5.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOE—glaucoma	9.25e-06	5.57e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CAV1—glaucoma	9.17e-06	5.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—glaucoma	9.05e-06	5.45e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTM1—glaucoma	9e-06	5.41e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1B—glaucoma	8.98e-06	5.4e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—glaucoma	8.97e-06	5.4e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—glaucoma	8.9e-06	5.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.81e-06	5.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FN1—glaucoma	8.73e-06	5.25e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCA1—glaucoma	8.7e-06	5.24e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1B1—glaucoma	8.7e-06	5.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BAD—glaucoma	8.62e-06	5.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1B—glaucoma	8.58e-06	5.16e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTM1—glaucoma	8.5e-06	5.12e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ABCA1—glaucoma	8.49e-06	5.11e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1B1—glaucoma	8.49e-06	5.11e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—glaucoma	8.49e-06	5.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TXN—glaucoma	8.47e-06	5.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—glaucoma	8.32e-06	5.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.03e-06	4.83e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCA1—glaucoma	8e-06	4.82e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1B1—glaucoma	8e-06	4.82e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—glaucoma	7.95e-06	4.78e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1B1—glaucoma	7.93e-06	4.77e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCA1—glaucoma	7.93e-06	4.77e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—glaucoma	7.75e-06	4.66e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—glaucoma	7.74e-06	4.66e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—glaucoma	7.51e-06	4.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—glaucoma	7.47e-06	4.49e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—glaucoma	7.4e-06	4.45e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAV1—glaucoma	7.33e-06	4.41e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—glaucoma	7.08e-06	4.26e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—glaucoma	7.03e-06	4.23e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—glaucoma	6.99e-06	4.21e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—glaucoma	6.96e-06	4.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—glaucoma	6.93e-06	4.17e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAV1—glaucoma	6.93e-06	4.17e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—glaucoma	6.85e-06	4.12e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—glaucoma	6.79e-06	4.09e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—glaucoma	6.78e-06	4.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—glaucoma	6.57e-06	3.95e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—glaucoma	6.41e-06	3.86e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—glaucoma	6.4e-06	3.85e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—glaucoma	6.38e-06	3.84e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—glaucoma	6.34e-06	3.82e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAV1—glaucoma	6.32e-06	3.8e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—glaucoma	6.15e-06	3.7e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—glaucoma	6.01e-06	3.61e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—glaucoma	6e-06	3.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—glaucoma	5.72e-06	3.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAV1—glaucoma	5.67e-06	3.41e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—glaucoma	5.65e-06	3.4e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—glaucoma	5.64e-06	3.4e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—glaucoma	5.61e-06	3.37e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—glaucoma	5.59e-06	3.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—glaucoma	5.56e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—glaucoma	5.55e-06	3.34e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAV1—glaucoma	5.53e-06	3.33e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—glaucoma	5.26e-06	3.17e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—glaucoma	5.24e-06	3.15e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCA1—glaucoma	5.23e-06	3.15e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1B1—glaucoma	5.23e-06	3.15e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—glaucoma	5.22e-06	3.14e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAV1—glaucoma	5.22e-06	3.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAV1—glaucoma	5.17e-06	3.11e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—glaucoma	5.07e-06	3.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—glaucoma	4.99e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—glaucoma	4.79e-06	2.88e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—glaucoma	4.78e-06	2.87e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—glaucoma	4.37e-06	2.63e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—glaucoma	4.29e-06	2.58e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—glaucoma	4.18e-06	2.52e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—glaucoma	4.18e-06	2.52e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—glaucoma	3.94e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—glaucoma	3.92e-06	2.36e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—glaucoma	3.91e-06	2.35e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—glaucoma	3.83e-06	2.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—glaucoma	3.77e-06	2.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—glaucoma	3.7e-06	2.22e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—glaucoma	3.61e-06	2.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—glaucoma	3.58e-06	2.15e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—glaucoma	3.44e-06	2.07e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAV1—glaucoma	3.41e-06	2.05e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—glaucoma	2.58e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—glaucoma	2.36e-06	1.42e-05	CbGpPWpGaD
